Duration of the pharmacodynamic interaction between pancuronium and mivacurium

被引:3
|
作者
Beaussier, M [1 ]
Deriaz, H [1 ]
De Traverse, A [1 ]
Abdelhalim, Z [1 ]
Lienhart, A [1 ]
机构
[1] St Antoine Hosp, Dept Anaesthesiol & Intens Care, Paris, France
关键词
antagonists; neuromuscular block; pancuronium; mivacurium; recovery;
D O I
10.1093/bja/81.2.251
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
The aim Of this study was to determine for how long the duration of action of increments of mivacurium can be influenced by previous pancuronium administration. Fifteen patients, ASA I or II, undergoing general anaesthesia for major abdominal surgery were investigated. The post-tetanic count (PTC) was measured at the adductor pollicis muscle. Pancuronium 0.1 mg kg(-1) was injected first. At recovery of the 10th response of the PTC (PTC10), a second dose of pancuronium was injected (0.02 mg kg(-1)). On recovery to PTC10, a bolus of mivacurium (0.04 mg kg(-1)) was given and regularly repeated at recovery of PTC10 until the end of surgery. The mean duration of the second dose of pancuronium was 53 min (SD 13 min) and of the first dose of mivacurium, 66 min (SD 14 min) (P<0.01). The duration of action of further mivacurium boluses decreased significantly until the fifth dose. It took 222 minutes (95% confidence interval 190, 253 min) after the second pancuronium dose before the duration of action of mivacurium returned to normal values and became constant and predictable.
引用
收藏
页码:251 / 252
页数:2
相关论文
共 50 条
  • [31] PANCURONIUM MAKES MIVACURIUM A LONG-ACTING MUSCLE-RELAXANT
    ERKOLA, O
    RAUTOMA, P
    MERETOJA, OA
    ANESTHESIOLOGY, 1994, 81 (3A) : A1061 - A1061
  • [32] PROLONGED NEUROMUSCULAR BLOCKADE WHEN MIVACURIUM AND PANCURONIUM WERE ADMINISTERED IN SERIES
    HERSCHMAN, Z
    PAMAAR, CG
    JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY, 1995, 33 (03): : 271 - 272
  • [33] INTERACTION BETWEEN PANCURONIUM-BROMIDE AND VECURONIUM BROMIDE
    RASHKOVSKY, OM
    AGOSTON, S
    KET, JM
    BRITISH JOURNAL OF ANAESTHESIA, 1985, 57 (11) : 1063 - 1066
  • [34] DOSE-RESPONSE STUDIES OF THE INTERACTION BETWEEN MIVACURIUM AND SUXAMETHONIUM
    NAGUIB, M
    ABDULATIF, M
    SELIM, M
    ALGHAMDI, A
    BRITISH JOURNAL OF ANAESTHESIA, 1995, 74 (01) : 26 - 30
  • [35] The interaction between prognostic and pharmacodynamic biomarkers
    L Bouranis
    M Sperrin
    A Greystoke
    C Dive
    A G Renehan
    British Journal of Cancer, 2013, 109 : 1782 - 1785
  • [36] A new pharmacokinetic/pharmacodynamic model (PK/PD) for mivacurium
    Laurin, J
    Nekka, F
    Donati, F
    Varin, F
    ANESTHESIOLOGY, 1996, 85 (3A) : A323 - A323
  • [37] Pharmacodynamic interaction between ezetimibe and rosuvastatin
    Kosoglou, T
    Statkevich, P
    Yang, B
    Suresh, R
    Zhu, Y
    Maxwell, SE
    Tiessen, R
    Cutler, DL
    ATHEROSCLEROSIS SUPPLEMENTS, 2004, 5 (01) : 153 - 153
  • [38] Pharmacodynamic interaction between ezetimibe and rosuvastatin
    Kosoglou, T
    Statkevich, P
    Yang, B
    Suresh, R
    Zhu, YL
    Boutros, T
    Maxwell, SE
    Tiessen, R
    Cutler, DL
    CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (08) : 1185 - 1195
  • [39] The interaction between prognostic and pharmacodynamic biomarkers
    Bouranis, L.
    Sperrin, M.
    Greystoke, A.
    Dive, C.
    Renehan, A. G.
    BRITISH JOURNAL OF CANCER, 2013, 109 (07) : 1782 - 1785
  • [40] PHARMACODYNAMIC INTERACTION BETWEEN ALPIDEM AND LORAZEPAM
    PATAT, A
    PERRAULT, MC
    VANDEL, B
    ZIELENIUK, I
    BROHIER, S
    MORSELLI, PL
    ROSENZWEIG, P
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (02) : 134 - 134